Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wp-cerber domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /www/htdocs/w00e14a1/CPC-NEU2021/wp-includes/functions.php on line 6114
Portugal - Chameleon Pharma Consulting
+49 30 648 35 164 service@chameleon-pharma.com

Portugal

Center of Lisbon in Portugal with terrasses, traditionnal and colorful houses

Featured image: Photo by Paulo Evangelista on Unsplash

Portugal’s Prescription Drugs and Consumer Healthcare market development

Portugal’s Prescription Drugs and Consumer Healthcare industry is undergoing evolutions and changes, showing potential for the future of its market. 

With an area of about 92,200 km² and over 10.3 mil­lion inhab­i­tants, Por­tu­gal occu­pies most of the west­ern part of the Iber­ian Penin­sula. The Por­tuguese OTC and pharma mar­ket size is worth USD 4,1 bil­lion, which has become one of the drivers of the overall GDP growth.

The country has a 20.8% of share in health expenditure. 59.7% of the market share is in Rx medicines, 32.6% in Hospital medicines, and 7.7% in OTC medicines.

The OTC market is mainly comprised of digestive and intestinal remedies, skin treatment products, cardiovascular remedies, cough and cold, analgesics, vitamins and minerals, and cardiovascular remedies among others. 

The OTC and pharma industry contributed to Portugal´s economy through its innovation, direct production, revenues, and jobs, and indirectly through the value chain, it impacts. It creates around 10,000 direct jobs and around 40,000 indirect jobs including transportation and trade of pharmaceuticals.

Portugal invested  €91 Million Euros in 2019 to Research and Development of which 96% came from the country’s own funds. 

Portugal’s OTC and pharma industry lags behind the EU countries’ markets. The share of GDP associated with this industry is half of that of Spain and a third less than Italy. However, the country has opportunities to grow in the future by innovating patient care, focusing on boosting prevention and diagnosis, increasing integrated patient care, and leveraging healthcare technology. Also by accelerating access to innovative medicines.

The consumer health and Rx industry in Portugal is growing and has the opportunity for expanding. If you want to take advantage of this growing market, Chameleon Pharma Consulting Group is here to assist you!

Portugal OTC and pharma market in 2035

USD 5,55 Billion

OTC and pharma market size, ex-factory

2-3%

OTC and pharma market growth

Portugal in numbers

Total population

Male/Female

Population growth

Birth rate

Mortality rate

Life expectancy

Interested in this market?

We are ready to support you in Strategy, Marketing, Systematic International Company Partner Identification, Commercial Due Diligence, Business Development, Acquisition Search, Regulatory projects, and more in order to ensure your growth.

Our services

i

International Strategy & Analysis

Licensing and
M&A

International Business & Market Entry

Pharma Regulatory & Registration

U

Product Potential & Country Analysis

Pharma Executive
Search

International Company Partner Identification

Market Reports and Analysis